AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03279380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Continuous Training
Description: The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
Study NCT01695473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM120
Description: Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
Study NCT01148537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5, 10, 20, and 2 \* 20 mcg/h.
Study NCT01148537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo transdermal patch
Description: Placebo transdermal patch to match BTDS 5, 10, 20, and 2 \* 20.
Study NCT01148537 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avelox (moxifloxacin hydrochloride) tablet
Description: Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
Study NCT01784965 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: liraglutide
Description: Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
Study NCT01784965 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
Study NCT02368717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine Enema
Study NCT02368717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Enema
Study NCT01678183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Financial Incentive
Description: A cash payment.
Study NCT01678183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Final Financial Incentive
Description: One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
Study NCT03687216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HVPG-guided therapy
Description: The baseline HVPG measurement is performed. According to the result, patients with an HVPG over 20 mmHg will be receive transjugular intrahepatic portocaval shunt (TIPS) .~Patients with an HVPG below 20 mmHg will be treated by endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol until treatment fails.
Study NCT03687216 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Routing Therapy
Description: Without HVPG measurement, patients receive endoscopic variceal ligation (EVL) plus nonselective beta blocker (NSBB) propranolol.
Study NCT00874978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
Study NCT01090401 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linox smart S DX
Description: ICD lead
Study NCT04044131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metabolic Cofactor Supplementation
Description: Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside. Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
Study NCT04044131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorbitol
Description: As placebo, sorbitol (5g) flavoured with strawberry aroma and colouring agent will be given.
Study NCT01405261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral NNC 0113-0987
Description: Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
Study NCT01405261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I.v. NNC 0113-0987
Description: Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
Study NCT01405261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: Subjects will be randomised to receive a single dose of placebo.
Study NCT04001361 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser Cell Therapy
Description: Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
Study NCT04001361 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laser Cell Therapy
Description: Bone marrow aspirate combined with laser to alter the cartilage matrix to facilitate repair
Study NCT03685786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART19 cell and auto-HSCT
Description: Phase 1 Clinical Study of CD19-directed Chimeric Antigen Receptor-modified T (CART19) Cells treatment for Adult Patient with Minimal Residual Disease(MRD) of B Cell Malignancies and then Autologous Hematopoietic Stem Cell Transplantation(Auto-HSCT). Subjects will receive 0.5-4 x 10\^8 transduced CAR T cells as a split dose over three days as follows:Day 0, 10% fraction: 0.5-4x10\^7 CART19 cells, Day 1, 30% fraction: 1.5x10\^7-1.2x10\^8 CART19 cells, Day 2, 60% fraction: 3x10\^7-2.4x10\^8 CART19 cells. Auto-HSCT will be made about 6 mouths after CART19 cell is infused back to the patient.
Study NCT02072655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socio-aesthetic care
Description: * care of the face~* skin cleansing with cleansing milk to remove impurities~* a gentle scrub to exfoliate and cleanse the skin~* a relaxing massage~* moisturizing mask~* application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...~* care manicure / pedicure,~* massages~* makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship.
Study NCT01266863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E test method
Description: E test strips directly applied to BAL
Study NCT03223064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ferumoxtran-10 enhanced MRI; MRI contrast agent
Description: Patient undergo MRI with an USPIO contrast agent
Study NCT03223064 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga PSMA PET-CT
Description: Patient undergo an 68Ga PSMA PET-CT scan
Study NCT01687764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Treatment (ABMT) - Active
Description: The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (\< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
Study NCT01687764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Attentional Bias Modification Treatment - Placebo
Description: The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
Study NCT01687764 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Attentional Bias Modification Treatment - Placebo
Description: The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
Study NCT01687764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy
Description: FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children
Study NCT01687764 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducational Control Intervention
Description: Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
Study NCT01687764 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychoeducational Control Intervention
Description: Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
Study NCT02277509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese DPP
Description: The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.~.
Study NCT02277509 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Minimal Intervention Control
Description: Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
Study NCT00919503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Infused IV
Study NCT00919503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Given IV
Study NCT00919503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Given IV or PO
Study NCT00919503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV
Study NCT00919503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00919503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT00919503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given IV or PO
Study NCT00919503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Infused IV
Study NCT00919503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT00919503 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo total body irradiation
Study NCT00919503 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treosulfan
Description: Given IV
Study NCT00919503 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Transplantation
Description: Single or double unit umbilical cord blood transplant, infused IV
Study NCT04293861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HYMOVIS
Description: HYMOVIS is a clear hydrogel obtained by hydration of the HA-based derivative named HYADD4p5. The conjugate compound is constituted by a partial hexadecylamide of hyaluronic acid, which is produced by a fermentation process.
Study NCT03725748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: irrigation
Description: irrigation the edges of the cs scar before closure
Study NCT03725748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: irrigation
Description: irrigation the edges of the cs scar before closure
Study NCT00160459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 5 mg Tablet, oral Daily for 12 weeks
Study NCT00160459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 10 mg Tablet, oral Daily for 12 weeks
Study NCT00160459 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asoprisnil
Description: 25 mg Tablet, oral Daily for 12 weeks
Study NCT00160459 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, oral Daily for 12 weeks
Study NCT03177772 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pre-loss group therapy
Description: The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
Study NCT05097456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide laser
Description: carbon dioxide laser
Study NCT05097456 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham laser
Description: sham laser
Study NCT03740256 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAdVEC
Description: The intratumoral administration of CAdVEC will create a pro-inflammatory tumor microenvironment and will promote the recruitment and expansion of adoptively transferred HER2 specific CAR T cells via CAR (tumor antigen). We expect HER2 CAR T cells expanded at primary tumor sites will re-circulate and target metastasized tumors. The combination we propose to test has the potential to overcome each of the established individual limitations of oncolytic viruses and of CAR T-cells. Testing each element separately would not be beneficial or informative, since the combination therapy is anticipated to have unique profiles of both therapeutic benefit and potential toxicities.
Study NCT03915223 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: leg fracture
Description: Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
Study NCT03915223 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: leg fracture
Description: Surgical leg fracture with injection of solumedrol (steroidal anti-inflammatory drug) or physiological serum
Study NCT02918773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone otoscope
Description: A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
Study NCT02918773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional otoscope
Description: A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
Study NCT03934450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPQ
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Study NCT03934450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPQ
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Study NCT03934450 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine Phosphate
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Study NCT03934450 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study will compare the individual enantiomers of primaquine - R- (-)-PQ, S-(+)-PQ, and Placebo along with the racemic version.
Study NCT02891304 — intervention group
Intervention type: OTHER
Intervention: Quarterly Feedback
Description: Learning curves received quarterly vs. annually
Study NCT04344587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-prone position recommendation
Description: The Qualtrics self-prone position recommendation intervention website will include the following sections:~1. Welcome message~2. Educational review of the potential benefits of prone positioning~3. How-To guide to safely prone in a hospital bed~4. A recommendation to prone while lying in bed (4 times for 1-2 hours each during the day and at night every 24 hours).~5. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking
Study NCT04344587 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: The Qualtrics usual care website will include the following sections:~1. Welcome message~2. A reminder to keep track of the time spent in 1) prone position, 2) lying flat on back, 3) lying on side, 4) sitting up, and 5) standing or walking
Study NCT01355939 — intervention group
Intervention type: PROCEDURE
Intervention: Clinically-Indicated Abdominal Re-Exploration Surgery
Description: This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
Study NCT04435600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risankizumab
Description: Subcutaneous Injection
Study NCT04435600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab
Description: Subcutaneous Injection
Study NCT04077437 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapy
Description: Standardized non-directive therapy performed by therapist team.
Study NCT01073566 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Finesse
Description: Finesse Insulin Delivery Patch
Study NCT01073566 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pen/Syringe (Usual injection device)
Description: Pen/Syringe
Study NCT04077437 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Therapy
Description: Standardized non-directive therapy performed by therapist team.
Study NCT04077437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midomafetamine
Description: Administration of 80 to 120 mg midomafetamine HCl, followed by a supplemental half-dose 1.5 to 2 hrs after the initial dose of 40 or 60 mg, respectively, during three sessions of MDMA-assisted psychotherapy.
Study NCT04077437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo with therapy during three experimental sessions
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 1
Description: Guselkumab will be administered by IV infusion.
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 2
Description: Guselkumab will be administered by SC injection.
Study NCT03466411 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guselkumab Dose 3
Description: Guselkumab will be administered by IV infusion.
Study NCT04623450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoothie
Description: Preload smoothies that are matched for taste, smell, appearance, quantity and calorie but different caloric content.
Study NCT01968135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combined Oral Contraceptive Pill
Description: 150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
Study NCT01968135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sugar Pill
Description: Placebo Sugar Pill
Study NCT02917889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
Study NCT02917889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
Study NCT02917889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary test
Description: assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.~.
Study NCT02917889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill aerobic exercise
Description: 30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
Study NCT03449823 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler ultrasound of fetal renal artery
Description: Doppler ultrasound assessment of the proximal fetal renal artery to with measurement of the peak systolic velocity, resistive index, pulsatility index, and systolic/diastolic ratio.